Sight Sciences (NASDAQ:SGHT) Rating Lowered to “Hold” at Wall Street Zen

Sight Sciences (NASDAQ:SGHT – Get Free Report) was downgraded by Wall Street Zen from a “buy” rating to a “hold” rating in a note issued to investors on Saturday, Wall Street Zen reports.

Several other research analysts have also weighed in on SGHT. Weiss Ratings reiterated a “sell (e+)” rating on shares of Sight Sciences in a report on Wednesday, November 4th. UBS Group boosted their target price on Sight Sciences from $8.00 to $13.50 and gave the company a “buy” rating in a research note on Thursday. Citigroup increased their price target on Sight Sciences from $8.00 to $10.00 and gave the stock a “neutral” rating in a report on Monday, October 5th. Piper Sandler reaffirmed an “overweight” rating and set a $12.00 price target (up from $9.00) on shares of Sight Sciences in a research report on Thursday, November 5th. Finally, HC Wainwright started coverage on Sight Sciences in a research report on Thursday, October 15th. They set a “buy” rating and a $14.00 price target on the stock. Five investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $10.31.

Get Our Latest Stock Analysis on SGHT

Sight Sciences Stock Performance

NASDAQ SGHT opened at $10.83 on Friday. Sight Sciences has a 12 month low of $3.38 and a 12 month high of $11.60. The stock has a 50-day simple moving average of $8.97 and a 200 day simple moving average of $6.20. The company has a current ratio of 5.04, a quick ratio of 4.72 and a debt-to-equity ratio of 0.71. The company has a market capitalization of $601.93 million, a PE ratio of -20.83 and a beta of 2.44.

Sight Sciences (NASDAQ:SGHT – Get Free Report) last announced its quarterly earnings results on Wednesday, November 4th. The company reported ($0.12) EPS for the quarter, meeting analysts’ consensus estimates of ($0.12). Sight Sciences had a negative return on equity of 43.91% and a negative net margin of 32.13%. The company had revenue of $24.92 million during the quarter, compared to analysts’ expectations of $23.55 million. Research analysts forecast that Sight Sciences will post -0.48 EPS for the current year.

Insider Transactions at Sight Sciences

In other Sight Sciences news, CEO Paul Badawi sold 29,653 shares of the business’s stock in a transaction that occurred on Thursday, October 1st. The stock was sold at an average price of $9.05, for a total value of $268,359.65. Following the sale, the chief executive officer owned 6,092,819 shares in the company, valued at approximately $55,140,011.95. The trade was a 0.48% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO James Rodberg sold 7,208 shares of the business’s stock in a transaction that occurred on Friday, October 2nd. The shares were sold at an average price of $8.85, for a total value of $63,790.80. Following the completion of the sale, the chief financial officer owned 216,829 shares in the company, valued at $1,918,936.65. The trade was a 3.22% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 47,646 shares of company stock worth $429,157 in the last 90 days. 30.40% of the stock is owned by corporate insiders.

Institutional Trading of Sight Sciences

A number of institutional investors have recently made changes to their positions in the business. Conquis Financial LLC acquired a new position in shares of Sight Sciences during the 2nd quarter worth about $27,000. The Manufacturers Life Insurance Company acquired a new stake in shares of Sight Sciences in the second quarter valued at about $60,000. Ieq Capital LLC acquired a new stake in shares of Sight Sciences in the second quarter valued at about $135,000. Hsbc Holdings PLC acquired a new stake in shares of Sight Sciences in the first quarter valued at about $147,000. Finally, Algert Global LLC raised its holdings in Sight Sciences by 25.3% during the second quarter. Algert Global LLC now owns 28,266 shares of the company’s stock worth $153,000 after acquiring an additional 5,706 shares in the last quarter. Institutional investors own 55.51% of the company’s stock.

About Sight Sciences

(Get Free Report)

Sight Sciences is a medical technology company that develops and commercializes devices for ophthalmic care, with a focus on glaucoma and dry eye disease. Its products are designed to support minimally invasive procedures and address underlying causes of these conditions. The company’s portfolio includes the OMNI Surgical System, used in procedures to reduce eye pressure in patients with glaucoma, and TearCare, a device-based treatment for evaporative dry eye associated with meibomian gland dysfunction.

Recommended Stories

Analyst Recommendations for Sight Sciences (NASDAQ:SGHT)

Receive News & Ratings for Sight Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sight Sciences and related companies with MarketBeat.com's FREE daily email newsletter.